Trial Profile
PD-1 gene knocked out CD19/CD20/CD22/CD30-CART Treatment in Relapsed/Refractory CD19/CD20/ CD22/CD30+ Non Hodgkin Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Oct 2018 New trial record